touchPANEL DISCUSSION
Back to Education Zone

touchPANEL DISCUSSION

Advanced soft tissue sarcoma – how can we address current controversies to solve a dilemma in clinical decision making?

Introduction

Watch a panel of internationally renowned experts discuss the factors influencing the choice of first-line treatment for patients with advanced soft tissue sarcoma (STS), the clinical unmet needs in this patient population and the potential of treatments in development to improve outcomes.

Dr. Marie Ahlström and Prof. Robin Jones co-chair discussions with Dr. Neeta Somaiah and Prof. Bruno Vincenzi that provide context for recent clinical study results as well as looking to the future with a review of emerging treatments that show promise for patients with STS.

This activity is intended for European oncologists involved in the treatment and management of patients with soft tissue sarcoma and other allied healthcare professionals.

This touchPANEL DISCUSSION was recorded in January 2019.

Learning Objectives

After watching this touchPANEL DISCUSSION, you should be better able to:

  • Describe first-line treatment options for patients with advanced soft tissue sarcoma (STS)
  • Understand how patient selection may affect treatment choice and outcome in advanced STS
  • Discuss how surrogate markers can be used in trial design to assess treatment outcomes in advanced STS

Clinical Spotlight

  • What influences the choice of first-line treatment for patients with advanced soft tissue sarcoma (STS)? Focus on patient and disease characteristics.
  • Why are positive results in Phase II clinical studies sometimes not supported by the Phase III data? Focus on interpreting complex clinical data.
  • How might treatments in development, which have different mechanisms of action, improve patient outcomes? Focus on personalizing therapy.

Clinical Spotlight

  • What influences the choice of first-line treatment for patients with advanced soft tissue sarcoma (STS)? Focus on patient and disease characteristics.
  • Why are positive results in Phase II clinical studies sometimes not supported by the Phase III data? Focus on interpreting complex clinical data.
  • How might treatments in development, which have different mechanisms of action, improve patient outcomes? Focus on personalizing therapy.
Download Slides

The Expert Panel

DR. AHLSTRÖM

PROFESSOR JONES

DR. SOMAIAH

PROFESSOR VINCENZI

DR. AHLSTRÖM

Maria Ahlström, MD is Head of the Medical Oncology Group in Sarcoma and Lymphoma at Skåne University Hospital, Lund, Sweden.
Dr. Ahlström is a specialist in the treatment of bone and soft tissue sarcomas and is active in the Scandinavian Sarcoma Group.

Disclosures: Nothing to disclose.

PROFESSOR JONES

Robin Jones, BSc, MB BS, MRCP, MD is a Medical Oncologist and is Head of the Sarcoma Unit at The Royal Marsden NHS Foundation Trust, London, UK. He specializes in the treatment of bone and soft tissue sarcomas. Professor Jones has experience in conducting Phase I, II and III trials, as well translational studies in sarcoma.

Disclosures: Honoraria and consulting from Adaptimmune, Blueprint, Clinigen, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Epizyme, Immune Design, Merck and PharmaMar. Research grant from MSD.

DR. SOMAIAH

Neeta Somaiah, MD is Associate Professor in Medical Oncology at the Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, US.  Dr. Somaiah has experience in conducting clinical trials and translational studies in sarcoma, which has enabled the development of novel therapeutic options including vaccine-based therapy, adoptive T-cell therapy and checkpoint inhibitor combinations.

Disclosures: Consulting for Bayer, Blueprint, Deciphera and Eli Lilly.

PROFESSOR VINCENZI

Bruno Vincenzi MD, PhD is Associate Professor in Medical Oncology at the Campus Bio-Medico University in Rome, Italy. Professor Vincenzi is actively involved in clinical and translational research, including the clinical and molecular aspects of solid tumours, the study of angiogenesis in cancer and the development of anti-angiogenic drugs.

Disclosures: Honoraria for lectures and consulting from Abbott, Bayer, Eisai, Eli Lilly, Novartis, Pfizer and PharmaMar.

Please feedback on this touchPANEL DISCUSSION on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).